Drug reference

Lanreotide

Somatostatin Analogue · Pituitary and Hypothalamic Hormones and Analogues

Also known as SOMATULINE AUTOGEL, SOMATULINE LA

Somatostatin AnaloguePituitary and Hypothalamic Hormones and AnaloguesATC H01CB03

CDSCO approvedATC H01CB03

EXCRETION

—

not curated

INTERACTIONS

2 major

SEVERE in our sources

PREGNANCY

Manufacturer advises use only if potential benefit outweighs risk.

FDA category + note

Top interactions

LonafarnibSevereDatabaseDDInter
PexidartinibSevereDatabaseDDInter

Mechanism

Lanreotide is a somatostatin analogue. It acts by mimicking natural somatostatin, inhibiting the secretion of various hormones. This action is utilized in treating conditions such as acromegaly and neuroendocrine tumours, and also to reduce gastric acid secretion, which can increase stoma output.

Indications

Acromegaly (if somatostatin analogue not given previously)Neuroendocrine (particularly carcinoid) tumoursUnresectable locally advanced or metastatic gastroenteropancreatic neuroendocrine tumours of midgut, pancreatic or unknown origin where hindgut sites of origin have been excludedThyroid tumoursAcromegalySymptoms associated with metastatic carcinoid tumors (e.g., flushing and diarrhea)Adenomas secreting VIP (e.g., watery diarrhea)Thyrotrope adenomas that oversecrete TSH (failed surgery)Severe secretory diarrheaCarcinoid tumorsGlucagonomasVIPomasCushing diseasePharmacotherapy of acromegalyTreatment of carcinoid syndromeControl of tumor growth in advanced well- or moderately differentiated gastroenteropancreatic neuroendocrine tumors (NETs)

Dosing

Adult: For SOMATULINE AUTOGEL (deep subcutaneous injection): Acromegaly: Initially 60 mg every 28 days, adjusted according to response; dose given in the gluteal region. Neuroendocrine (particularly carcinoid) tumours: Initially 60–120 mg every 28 days, adjusted according to response; dose given in the gluteal region.…

Pharmacokinetics

Duration

10–15 days (on i.m. injection)

Side effects

Common

AlopeciaAppetite decreasedAstheniaCholecystitisCholelithiasis (following long term use)CholestasisConstipationDiabetes mellitusDiarrhoeaDizzinessGastrointestinal discomfortGastrointestinal disordersGlucose tolerance impaired (following long term use)HeadacheHyperglycaemia (long term use)HypoglycaemiaMyalgiaNauseaPruritusSinus bradycardiaVomitingBiliary dilatationLethargyMusculoskeletal painWeight decreasedDiarrheaAbdominal painMultiple tiny gallstones (presumably due to decreased gallbladder contraction and bile secretion)BradycardiaQT prolongationHypothyroidism (rare)Worsening or improvement in glucose toleranceGI symptomsMild nauseaAbdominal discomfortBloatingLoose stools (usually subside after 1-2 months)Mild glucose intolerance

Serious

Growth hormone-secreting pituitary tumour expansion (causing serious complications)
Pancreatitis
Gallbladder abnormalities (stones and biliary sludge)
Pancreatic insufficiency (with persistent bloating/loose stools)
Impaired gallbladder contractility
Increased risk of cholelithiasis